Abstract
SARS-CoV-2 testing is crucial to controlling the spread of this virus, yet shortages of nucleic acid extraction supplies and other key reagents have hindered the response to COVID-19 in the US. Several groups have described loop-mediated isothermal amplification (LAMP) assays for SARS-CoV-2, including testing directly from nasopharyngeal swabs and eliminating the need for reagents in short supply. Here we describe a fluorescence-based RT-LAMP test using direct nasopharyngeal swab samples and show consistent detection in clinically confirmed samples, albeit with approximately 100-fold lower sensitivity than qRT-PCR. We demonstrate that adding lysis buffer directly into the RT-LAMP reaction improves the sensitivity of some samples by approximately 10-fold. Overall, the limit of detection (LOD) of RT-LAMP using direct nasopharyngeal swab or saliva samples without RNA extraction is 1x105-1x106 copies/ml. This LOD is sufficient to detect samples from which infectious virus can be cultured. Therefore, samples that test positive in this assay contain levels of virus that are most likely to perpetuate transmission. Furthermore, purified RNA in this assay achieves a similar LOD to qRT-PCR and we provide a revised method to work directly with saliva as starting material. These results indicate that high-throughput RT-LAMP testing could augment qRT-PCR in SARS-CoV-2 screening programs, especially while the availability of qRT-PCR testing and RNA extraction reagents is constrained.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://openresearch.labkey.com/Coven/wiki-page.view?name=lamp-testing
Funding Statement
This work was supported in part by the Office of Research Infrastructure Programs/OD under grant P51OD011106 awarded to the Wisconsin National Primate Research Center at the University of Wisconsin-Madison, the Rapid Acceleration of Diagnostics (RADX) program through the National Institutes of Health (contract number pending), and by the Wisconsin Alumni Research Foundation COVID19 challenge.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Residual NP swab and saliva samples were provided by University of Wisconsin-Madison Hospitals and Clinics and the Wisconsin State Laboratory of Hygiene under biosafety protocol B00000117 (IRB 2016-0605) and their use was not considered human subjects research by the University of Wisconsin-Madison School of Medicine and Public Health's Institutional Review Board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Title, abstract, and discussion updated to better incorporate the work using saliva as the assay input material.
Data Availability
All data supporting the results are presented either in the main paper or as part of the supplemental online material.
